1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Hospital Universitario 12 De Octubre, LungenClinic Grosshansdorf, Kindai University Hospital, Kindai University, University of California, Los Angeles, Eli Lilly (Italy), Eli Lilly (United States), Eli Lilly (Netherlands), University of Turin
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Mirati Therapeutics, BeiGene, Boehringer Ingelheim Japan, Natera, Eisai, Astellas Pharma, Shionogi, Genentech, EMD Serono, Novartis Pharma, Pfizer Japan, Chugai Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Daiichi Sankyo Europe
OpenAlex ID: W3202463645